VCYT VERACYTE, INC.
Nasdaq · SEC CIK 1384101 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $22.25M 37 sales by 11 insiders
- Filings on record
- 275 since 2021-07-20, latest 2026-09-22 17:16
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Stapley Marc | CEO, Dir | — | $8.92M |
| JONES EVAN/ FA | Dir | — | $2.00M |
| Chambers Rebecca | CFO | — | $1.91M |
| McGuire Annie | SVP, GC | — | $1.80M |
| Wygant Jonathan | VP, CAO | — | $1.54M |
| EASTHAM KARIN | Dir | — | $1.49M |
| Febbo Phillip G. | Chief Scientific, Med Off | — | $1.35M |
| Leite John | Gbl Chief Commercial Off | — | $1.34M |
| EPSTEIN ROBERT S | Dir | — | $1.19M |
| Holstein Jens | Dir | — | $628.3K |
Transactions 342
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-09-22 17:16 | 2026-09-21 | VCYT | Leite John | Gbl Chief Commercial Off | S - Sale | $40.00 | -4,015 | 124.3K | -3% | -$160.6K |
| T | 2026-09-16 16:08 | 2026-09-14 | VCYT | Holstein Jens | Dir | S - Sale | $40.95 | -5,000 | 27.5K | -15% | -$204.7K |
| 2026-09-04 19:54 | 2026-09-02 | VCYT | Wygant Jonathan | VP, CAO | F - Tax | $44.88 | -1,361 | 43.2K | -3% | -$61.1K | |
| 2026-09-04 19:54 | 2026-09-02 | VCYT | Leite John | Gbl Chief Commercial Off | F - Tax | $44.88 | -3,961 | 128.3K | -3% | -$177.8K | |
| T | 2026-09-04 19:54 | 2026-09-02 | VCYT | Febbo Phillip G. | Chief Scientific, Med Off | F - Tax | $44.88 | -3,639 | 146.2K | -2% | -$163.3K |
| MT | 2026-09-04 19:54 | 2026-09-04 | VCYT | Febbo Phillip G. | Chief Scientific, Med Off | S - Sale | $43.05 | -13.1K | 133.0K | -9% | -$564.4K |
| T | 2026-09-04 19:54 | 2026-09-02 | VCYT | Chambers Rebecca | CFO | F - Tax | $44.88 | -3,603 | 169.7K | -2% | -$161.7K |
| MT | 2026-09-04 19:54 | 2026-09-04 | VCYT | Chambers Rebecca | CFO | S - Sale | $43.10 | -3,652 | 166.0K | -2% | -$157.4K |
| T | 2026-09-04 19:54 | 2026-09-02 | VCYT | McGuire Annie | EVP, GC | F - Tax | $44.88 | -3,215 | 134.4K | -2% | -$144.3K |
| MT | 2026-09-04 19:54 | 2026-09-04 | VCYT | McGuire Annie | EVP, GC | S - Sale | $43.09 | -3,254 | 131.2K | -2% | -$140.2K |
| 2026-09-04 19:53 | 2026-09-02 | VCYT | Stapley Marc | CEO, Dir | F - Tax | $44.88 | -8,782 | 432.1K | -2% | -$394.1K | |
| T | 2026-09-03 16:48 | 2026-09-01 | VCYT | Bhanji Muna | Dir | S - Sale | $42.97 | -1,864 | 42.7K | -4% | -$80.1K |
| MT | 2026-06-22 16:30 | 2026-06-18 | VCYT | EASTHAM KARIN | Dir | S - Sale | $52.89 | -3,729 | 15.1K | -20% | -$197.2K |
| 2026-06-15 16:56 | 2026-06-11 | VCYT | EASTHAM KARIN | Dir | A - Grant | $0.00 | +5,272 | 18.8K | +39% | $0 | |
| 2026-06-15 16:56 | 2026-06-11 | VCYT | JONES EVAN/ FA | Dir | A - Grant | $0.00 | +5,272 | 34.6K | +18% | $0 | |
| 2026-06-15 16:56 | 2026-06-11 | VCYT | Shafer David Brent | Dir | A - Grant | $0.00 | +5,272 | 31.1K | +20% | $0 | |
| 2026-06-15 16:56 | 2026-06-11 | VCYT | Barr Eliav | Dir | A - Grant | $0.00 | +5,272 | 56.5K | +10% | $0 | |
| 2026-06-15 16:55 | 2026-06-11 | VCYT | EPSTEIN ROBERT S | Dir | A - Grant | $0.00 | +5,272 | 57.7K | +10% | $0 | |
| 2026-06-15 16:55 | 2026-06-11 | VCYT | Holstein Jens | Dir | A - Grant | $0.00 | +5,272 | 32.5K | +19% | $0 | |
| 2026-06-15 16:55 | 2026-06-11 | VCYT | Bhanji Muna | Dir | A - Grant | $0.00 | +5,272 | 44.6K | +13% | $0 | |
| 2026-06-15 16:55 | 2026-06-11 | VCYT | Miller Thomas F. | Dir | A - Grant | $0.00 | +5,272 | 31.1K | +20% | $0 | |
| T | 2026-06-04 21:38 | 2026-06-02 | VCYT | McGuire Annie | EVP, GC | F - Tax | $47.80 | -3,292 | 140.4K | -2% | -$157.4K |
| MT | 2026-06-04 21:38 | 2026-06-04 | VCYT | McGuire Annie | EVP, GC | S - Sale | $49.76 | -3,176 | 137.2K | -2% | -$158.0K |
| 2026-06-04 21:38 | 2026-06-02 | VCYT | Wygant Jonathan | VP, CAO | F - Tax | $47.80 | -1,361 | 44.1K | -3% | -$65.1K | |
| T | 2026-06-04 21:38 | 2026-06-02 | VCYT | Chambers Rebecca | CFO | F - Tax | $47.80 | -3,693 | 176.8K | -2% | -$176.5K |
| MT | 2026-06-04 21:38 | 2026-06-04 | VCYT | Chambers Rebecca | CFO | S - Sale | $49.73 | -3,561 | 173.3K | -2% | -$177.1K |
| T | 2026-06-04 21:38 | 2026-06-02 | VCYT | Febbo Phillip G. | Chief Scientific, Med Off | F - Tax | $47.80 | -3,730 | 149.8K | -2% | -$178.3K |
| DT | 2026-06-04 21:38 | 2026-06-02 | VCYT | Stapley Marc | CEO, Dir | F - Tax | $47.80 | -9,012 | 440.5K | -2% | -$430.8K |
| DT | 2026-06-04 21:38 | 2026-06-04 | VCYT | Stapley Marc | CEO, Dir | M - OptEx | $36.60 | +138.1K | 578.5K | +31% | +$5.05M |
| DT | 2026-06-04 21:38 | 2026-06-04 | VCYT | Stapley Marc | CEO, Dir | S - Sale+OE | $50.12 | -138.1K | 440.5K | -24% | -$6.92M |
| T | 2026-06-04 21:38 | 2026-06-02 | VCYT | Leite John | Gbl Chief Commercial Off | F - Tax | $47.80 | -4,059 | 146.3K | -3% | -$194.0K |
| T | 2026-06-04 21:38 | 2026-06-04 | VCYT | Leite John | Gbl Chief Commercial Off | S - Sale | $50.07 | -14.0K | 132.3K | -10% | -$699.7K |
| D | 2026-05-27 16:19 | 2026-05-22 | VCYT | Wygant Jonathan | VP, CAO | M - OptEx | $24.80 | +24.0K | 69.4K | +53% | +$595.2K |
| D | 2026-05-27 16:19 | 2026-05-22 | VCYT | Wygant Jonathan | VP, CAO | S - Sale+OE | $45.40 | -24.0K | 45.4K | -35% | -$1.09M |
| T | 2026-05-22 16:39 | 2026-05-20 | VCYT | EPSTEIN ROBERT S | Dir | S - Sale | $44.01 | -10.0K | 52.4K | -16% | -$440.1K |
| MT | 2026-05-08 16:25 | 2026-05-06 | VCYT | McGuire Annie | SVP, GC | S - Sale | $39.02 | -10.2K | 143.7K | -7% | -$398.2K |
| 2026-04-14 17:03 | 2026-04-10 | VCYT | Haas Kevin Richard | Chief Dev, Tech Off | A - Grant | $0.00 | +44.2K | 44.2K | New | $0 | |
| M | 2026-03-10 | 2026-03-06 | VCYT | Leite John | Chief Commercial Off.-CLIA | A - Grant | $0.00 | +42.8K | 143.8K | +42% | $0 |
| M | 2026-03-10 | 2026-03-06 | VCYT | Febbo Phillip G. | Chief Scientific, Med Off | A - Grant | $0.00 | +36.2K | 146.9K | +33% | $0 |
| 2026-03-10 | 2026-03-06 | VCYT | Wygant Jonathan | VP, CAO | A - Grant | $0.00 | +10.5K | 45.4K | +30% | $0 | |
| 2026-03-10 | 2026-03-06 | VCYT | Stapley Marc | CEO, Dir | A - Grant | $0.00 | +92.1K | 449.7K | +26% | $0 | |
| M | 2026-03-10 | 2026-03-06 | VCYT | McGuire Annie | SVP, GC | A - Grant | $0.00 | +59.2K | 153.9K | +63% | $0 |
| M | 2026-03-10 | 2026-03-06 | VCYT | Chambers Rebecca | CFO | A - Grant | $0.00 | +49.3K | 180.5K | +38% | $0 |
| M | 2026-03-06 | 2026-03-04 | VCYT | Stapley Marc | CEO, Dir | S - Sale | $35.98 | -45.5K | 383.8K | -11% | -$1.64M |
| 2026-03-06 | 2026-03-04 | VCYT | Leite John | Chief Commercial Off.-CLIA | S - Sale | $35.19 | -5,260 | 107.6K | -5% | -$185.1K | |
| M | 2026-03-06 | 2026-03-04 | VCYT | Chambers Rebecca | CFO | S - Sale | $36.14 | -18.3K | 145.1K | -11% | -$662.9K |
| M | 2026-03-06 | 2026-03-04 | VCYT | McGuire Annie | SVP, GC | S - Sale | $35.55 | -6,658 | 94.7K | -7% | -$236.7K |
| 2026-03-04 | 2026-03-02 | VCYT | McGuire Annie | SVP, GC | F - Tax | $36.01 | -6,902 | 101.4K | -6% | -$248.5K | |
| 2026-03-04 | 2026-03-02 | VCYT | Stapley Marc | CEO, Dir | F - Tax | $36.01 | -19.5K | 403.1K | -5% | -$700.6K | |
| 2026-03-04 | 2026-03-02 | VCYT | Febbo Phillip G. | Chief Scientific, Med Off | S - Sale | $36.16 | -13.4K | 117.3K | -10% | -$485.4K | |
| 2026-03-04 | 2026-03-02 | VCYT | Febbo Phillip G. | Chief Scientific, Med Off | F - Tax | $36.01 | -6,035 | 130.8K | -4% | -$217.3K | |
| 2026-03-04 | 2026-03-02 | VCYT | Chambers Rebecca | CFO | F - Tax | $36.01 | -7,234 | 149.5K | -5% | -$260.5K | |
| 2026-03-04 | 2026-03-02 | VCYT | Leite John | Chief Commercial Off.-CLIA | F - Tax | $36.01 | -7,517 | 112.8K | -6% | -$270.7K | |
| 2026-03-04 | 2026-03-02 | VCYT | Wygant Jonathan | VP, CAO | F - Tax | $36.01 | -3,006 | 34.9K | -8% | -$108.2K | |
| 2026-03-02 | 2026-02-26 | VCYT | Chambers Rebecca | CFO | A - Grant | $0.00 | +59.3K | 168.8K | +54% | $0 | |
| 2026-03-02 | 2026-02-26 | VCYT | Chambers Rebecca | CFO | F - Tax | $38.75 | -12.0K | 156.8K | -7% | -$466.9K | |
| 2026-03-02 | 2026-02-26 | VCYT | Febbo Phillip G. | Chief Scientific, Med Off | F - Tax | $38.75 | -24.5K | 136.8K | -15% | -$948.8K | |
| 2026-03-02 | 2026-02-26 | VCYT | Febbo Phillip G. | Chief Scientific, Med Off | A - Grant | $0.00 | +71.8K | 161.3K | +80% | $0 | |
| 2026-03-02 | 2026-02-26 | VCYT | Stapley Marc | CEO, Dir | A - Grant | $0.00 | +139.1K | 458.4K | +44% | $0 | |
| 2026-03-02 | 2026-02-26 | VCYT | Stapley Marc | CEO, Dir | F - Tax | $38.75 | -35.8K | 422.5K | -8% | -$1.39M | |
| 2026-03-02 | 2026-02-26 | VCYT | McGuire Annie | SVP, GC | A - Grant | $0.00 | +51.0K | 119.1K | +75% | $0 | |
| 2026-03-02 | 2026-02-26 | VCYT | McGuire Annie | SVP, GC | F - Tax | $38.75 | -10.9K | 108.3K | -9% | -$421.1K | |
| 2026-03-02 | 2026-02-26 | VCYT | Leite John | Chief Commercial Off.-CLIA | A - Grant | $0.00 | +47.1K | 129.3K | +57% | $0 | |
| 2026-03-02 | 2026-02-26 | VCYT | Leite John | Chief Commercial Off.-CLIA | F - Tax | $38.75 | -8,905 | 120.4K | -7% | -$345.1K | |
| M | 2025-12-17 | 2025-12-16 | VCYT | McGuire Annie | SVP, GC | S - Sale | $43.14 | -10.7K | 67.8K | -14% | -$463.2K |
| DM | 2025-12-08 | 2025-12-05 | VCYT | EASTHAM KARIN | Dir | M - OptEx | $7.77 | +20.0K | 33.6K | +148% | +$155.4K |
| DM | 2025-12-08 | 2025-12-05 | VCYT | EASTHAM KARIN | Dir | S - Sale+OE | $45.45 | -20.0K | 27.2K | -42% | -$909.0K |
| 2025-12-04 | 2025-12-02 | VCYT | Wygant Jonathan | VP, CAO | F - Tax | $46.16 | -1,325 | 37.4K | -3% | -$61.2K | |
| 2025-12-04 | 2025-12-02 | VCYT | Febbo Phillip G. | Chief Scientific, Med Off | F - Tax | $46.16 | -2,955 | 89.5K | -3% | -$136.4K | |
| M | 2025-12-04 | 2025-12-04 | VCYT | McGuire Annie | SVP, GC | S - Sale | $47.30 | -1,422 | 78.5K | -2% | -$67.3K |
| 2025-12-04 | 2025-12-02 | VCYT | McGuire Annie | SVP, GC | F - Tax | $46.16 | -3,052 | 79.9K | -4% | -$140.9K | |
| M | 2025-12-04 | 2025-12-04 | VCYT | Chambers Rebecca | CFO | S - Sale | $46.84 | -13.3K | 114.2K | -10% | -$621.9K |
| 2025-12-04 | 2025-12-02 | VCYT | Chambers Rebecca | CFO | F - Tax | $46.16 | -3,384 | 122.8K | -3% | -$156.2K | |
| 2025-12-04 | 2025-12-02 | VCYT | Stapley Marc | CEO, Dir | F - Tax | $46.16 | -7,914 | 326.3K | -2% | -$365.3K | |
| M | 2025-12-04 | 2025-12-04 | VCYT | Stapley Marc | CEO, Dir | S - Sale | $47.09 | -7,668 | 318.6K | -2% | -$361.1K |
| 2025-12-04 | 2025-12-02 | VCYT | Leite John | Chief Commercial Off.-CLIA | F - Tax | $46.16 | -2,900 | 83.4K | -3% | -$133.9K | |
| 2025-12-04 | 2025-12-04 | VCYT | Leite John | Chief Commercial Off.-CLIA | S - Sale | $47.51 | -1,278 | 82.1K | -2% | -$60.7K | |
| 2025-11-26 | 2025-11-25 | VCYT | JONES EVAN/ FA | Dir | S - Sale | $50.25 | -1,106 | 29.4K | -4% | -$55.6K | |
| 2025-11-26 | 2025-11-25 | VCYT | Leite John | Chief Commercial Off.-CLIA | S - Sale | $50.00 | -2,808 | 86.3K | -3% | -$140.4K | |
| M | 2025-11-21 | 2025-11-20 | VCYT | Holstein Jens | Dir | S - Sale | $42.36 | -10.0K | 27.2K | -27% | -$423.6K |
| M | 2025-11-12 | 2025-11-07+ | VCYT | Wygant Jonathan | VP, CAO | S - Sale | $41.20 | -10.9K | 38.7K | -22% | -$449.9K |
| 2025-11-07 | 2025-11-05 | VCYT | McGuire Annie | SVP, GC | S - Sale | $40.00 | -6,466 | 83.0K | -7% | -$258.6K | |
| 2025-11-07 | 2025-11-05 | VCYT | Chambers Rebecca | CFO | S - Sale | $41.00 | -7,000 | 126.2K | -5% | -$287.0K | |
| 2025-11-07 | 2025-11-05 | VCYT | EASTHAM KARIN | Dir | S - Sale | $40.02 | -9,674 | 13.6K | -42% | -$387.2K | |
| DM | 2025-11-07 | 2025-11-05 | VCYT | JONES EVAN/ FA | Dir | M - OptEx | $6.94 | +30.0K | 53.7K | +127% | +$208.2K |
| DM | 2025-11-07 | 2025-11-05 | VCYT | JONES EVAN/ FA | Dir | S - Sale+OE | $45.06 | -43.2K | 73.3K | -37% | -$1.95M |
| 2025-10-30 | 2025-10-28 | VCYT | Wygant Jonathan | VP, CAO | A - Grant | $0.00 | +2,886 | 49.7K | +6% | $0 | |
| 2025-10-07 | 2025-10-06 | VCYT | Febbo Phillip G. | Chief Scientific, Med Off | S - Sale | $36.02 | -8,349 | 92.4K | -8% | -$300.7K | |
| D | 2025-10-03 | 2025-10-01 | VCYT | EPSTEIN ROBERT S | Dir | M - OptEx | $7.94 | +10.0K | 83.9K | +14% | +$79.4K |
| D | 2025-10-03 | 2025-10-01 | VCYT | EPSTEIN ROBERT S | Dir | S - Sale+OE | $35.08 | -21.5K | 62.4K | -26% | -$753.3K |
| 2025-10-03 | 2025-10-01 | VCYT | Leite John | Chief Commercial Off.-CLIA | S - Sale | $35.00 | -2,539 | 89.1K | -3% | -$88.9K | |
| 2025-10-03 | 2025-10-01 | VCYT | McGuire Annie | SVP, GC | S - Sale | $35.00 | -2,160 | 89.4K | -2% | -$75.6K | |
| 2025-09-23 | 2025-09-19 | VCYT | McGuire Annie | SVP, GC | S - Sale | $33.69 | -2,283 | 91.6K | -2% | -$76.9K | |
| 2025-09-08 | 2025-09-04 | VCYT | Stapley Marc | CEO, Dir | S - Sale | $30.41 | -7,667 | 334.2K | -2% | -$233.2K | |
| 2025-09-04 | 2025-09-02 | VCYT | Wygant Jonathan | VP, CAO | F - Tax | $30.11 | -1,648 | 46.8K | -3% | -$49.6K | |
| 2025-09-04 | 2025-09-02 | VCYT | Leite John | Chief Commercial Off.-CLIA | F - Tax | $30.11 | -2,902 | 91.6K | -3% | -$87.4K | |
| 2025-09-04 | 2025-09-02 | VCYT | McGuire Annie | SVP, GC | F - Tax | $30.11 | -3,507 | 93.9K | -4% | -$105.6K | |
| 2025-09-04 | 2025-09-02 | VCYT | Febbo Phillip G. | Chief Scientific, Med Off | F - Tax | $30.11 | -2,955 | 100.8K | -3% | -$89.0K | |
| 2025-09-04 | 2025-09-02 | VCYT | Chambers Rebecca | CFO | F - Tax | $30.11 | -5,371 | 133.2K | -4% | -$161.7K | |
| 2025-09-04 | 2025-09-02 | VCYT | Stapley Marc | CEO, Dir | F - Tax | $30.11 | -7,914 | 341.9K | -2% | -$238.3K |
Purchase Sale Sale after option exercise All abbreviations